160801-74-1

Basic information

• Product Name: Carbamic acid, [(1S)-1-formylbutyl]-, 1,1-dimethylethyl ester (9CI)
• Synonyms: Carbamic acid, [(1S)-1-formylbutyl]-, 1,1-dimethylethyl ester (9CI);Carbamic acid, N-[(1S)-1-formylbutyl]-;(2S)-2-(1,1-diMethylethoxycarbonylaMino)pentanal;CarbaMic acid, N-[(1S)-1-forMylbutyl]-, 1,1-diMethylethyl ester
• CAS NO: 160801-74-1
• Molecular Formula: C₁₀H₁₉NO₃
• Molecular Weight: 201.26276
• Product Categories: N-BOC
• Mol File: 160801-74-1.mol
• Article Data: 26

Chemical Properties

• Appearance: /
• CAS DataBase Reference: Carbamic acid, [(1S)-1-formylbutyl]-, 1,1-dimethylethyl ester (9CI)(CAS DataBase Reference)
• NIST Chemistry Reference: Carbamic acid, [(1S)-1-formylbutyl]-, 1,1-dimethylethyl ester (9CI)(160801-74-1)
• EPA Substance Registry System: Carbamic acid, [(1S)-1-formylbutyl]-, 1,1-dimethylethyl ester (9CI)(160801-74-1)

Safety Data

• Hazardous Substances Data: 160801-74-1(Hazardous Substances Data)

Upstream product

• 22724-81-8 L-norvalinol 
• 79-43-6 dichloro-acetic acid 
• 116611-57-5 tert-butyl [(1S)-1-(hydroxymethyl)butyl]carbamate 
• 24424-99-5 di-tert-butyl dicarbonate 
• 6600-40-4 L-Norvaline 
• 160801-73-0 (S)-tert-butyl 1-(methoxy(methyl)amino)-1-oxopentan-2-ylcarbamate 
• 64896-37-3 methyl N-{[(1,1-dimethylethyl)oxy]carbonyl}-L-norvalinate 
• 53308-95-5 N-tert-butoxycarbonyl-L-norvaline 

Downstream Products

• 896740-85-5 C₂₀H₃₀N₄O₄ 
• 896740-87-7 C₁₉H₂₇N₃O₅ 
• 850252-34-5 (3S)-3-amino-N-cyclopropyl-2-hydroxyhexanamide hydrochloride 
• 856707-38-5 acetic acid (2S)-2-tert-butoxycarbonylamino-1-cyclopropylcarbamoylpentyl ester 
• 160801-88-7 Boc-Phe-Leu-Nva-CONH-CH₂CH₃ 
• 160868-27-9 Boc-D-Phe-Leu-Nva-CONH-CH₂CH₃ 
• 209398-26-5 (3S)-3-(tert-butoxycarbonylamino)-2-hydroxyhexanoic acid 
• 402959-32-4 (S)-3-Amino-2-hydroxy-hexanoic acid 

Relevant articles and documents

Vinyl sulfone-based inhibitors of trypanosomal cysteine protease rhodesain with improved antitrypanosomal activities

The number of reported cases of Human African Trypanosmiasis (HAT), caused by kinetoplastid protozoan parasite Trypanosoma brucei, is declining in sub-Saharan Africa. Historically, such declines are generally followed by periods of higher incidence, and one of the lingering public health challenges of HAT is that its drug development pipeline is historically sparse. As a continuation of our work on new antitrypanosomal agents, we found that partially saturated quinoline-based vinyl sulfone compounds selectively inhibit the growth of T. brucei but displayed relatively weak inhibitory activity towards T. brucei's cysteine protease rhodesain. While two nitroaromatic analogues of the quinoline-based vinyl sulfone compounds displayed potent inhibition of T. brucei and rhodesain. The quinoline derivatives and the nitroaromatic-based compounds discovered in this work can serve as leads for ADME-based optimization and pre-clinical investigations.

COMPOUNDS THAT INHIBIT PROTEASE CATHEPSIN S AND HCV REPLICATION

The present invention is directed to compounds that have the dual property of acting as cathepsin S inhibitors and of inhibiting HCV replication. Such compounds are therefore useful in treating disease states that include hepatitis C, Alzheimer's disease,

HCV INHIBITORS

The present invention is directed to compounds that are antiviral agents. Specifically the compounds of the present invention inhibit replication of HCV and are therefore useful in treating hepatitis C infections. The present invention is also directed to pharmaceutical compositions comprising these compounds and processes for preparing them.